<DOC>
	<DOCNO>NCT00326339</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , double-blind , placebo-controlled , ascend dose , dose range study evaluate three dos R935788 ( 50 mg bid , 100 mg bid 150 mg bid ) . Approximately 180 patient rheumatoid arthritis minimum 12 month receive weekly methotrexate ( MTX ) dose minimum 6 month enrol study .</brief_summary>
	<brief_title>Treatment Arthritis With Syk Kinase Inhibition ( TASKI-1 )</brief_title>
	<detailed_description>The primary objective study assess preliminary efficacy three different dosage regimen R788 determine ACR 20 responder rate 12 week The secondary objective study assess safety three different dosage regimen R788 determine ACR 20 responder rate 12 week , assess general clinical laboratory safety evaluation throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Patients must give write informed consent sign IRBapproved Informed Consent Form ( ICF ) prior admission study . 2 . Males female , 18 75 year age , active RA least 12 month ( functional class IIII , e.g. , bed wheelchairbound ) receive weekly dos methotrexate ( 1025 mg/week ) minimum 180 day , receive stable MTX dose least 15 mg without change route change folic acid supplementation least 30 day . Active RA define presence ( ) 6 swollen joint ( 28 joint count ) ; AND ( b ) 6 tender joint ( 28 joint count ) ; AND ( c ) CRP level &gt; ULN central reference laboratory . Patient may receive 10 mg per day oral prednisone steroid equivalent , NSAID therapy , hydroxychloroquine , chloroquine , minocycline , sulfasalazine , doxycycline . The dose ( ) must stable least 30 day must change washout , screen treatment period , unless dictate tolerability requirement . 3 . Females childbearing potential must fully inform potential methotrexate R788 adversely affect fetus must agree use adequate ( 2 method ) contraception study . These patient must lactate must negative urine pregnancy test time randomization laboratory determination . 4 . The patient otherwise good health determine Investigator basis medical history , physical examination , laboratory screening test screen period , include absence clinically significant finding , HIV , HBV HCV , interstitial pneumonitis active pulmonary infection , chest Xray take within 6 month prior screen negative TB skin test , abnormal liver function define know ALT &gt; 1.2xULN within past 90 day . 5 . In investigator 's opinion , patient ability understand nature study hazard participation , communicate satisfactorily investigator participate , comply , requirement entire protocol . 1 . The patient history , concurrent , clinically significant illness , medical condition ( arthritis ) laboratory abnormality , Investigator 's opinion , could affect conduct study ( include exclusion log ) . 2 . The patient history substance abuse , drug addiction alcoholism . 3 . The patient unable abstain alcohol study . 4 . The patient recent ( past 5 year ) history , treatment , malignancy basal skin cancer . 5 . The patient receive investigational medication within 30 day prior admission study . 6 . Any patient receive following treatment must abide indicated washout period : 1. oral injectable gold , azathioprine , penicillamine , anakinra require 30 day washout period prior Day 1 dose 2. cyclosporine , abatacept , etanercept , infliximab adalimumab require 60 day washout period prior Day 1 dose 3. leflunomide require 60 day washout period prior screening , unless patient undergone cholestyramine washout least 30 day prior Day 1 dose 4. cyclophosphamide require 180 day washout period prior Day 1 dose 5 . Rituxan require 180 day washout period normal CD19 count prior Day 1 dose 6. parenteral intraarticular corticosteroid require 30 day washout period prior Day 1 dose 7 . Patients follow laboratory abnormality : ALT &gt; 1.2X ULN , creatinine &gt; ULN , neutrophil count &lt; 2,500/mm3 lymphocyte count &lt; 800/mm3 , Hgb &lt; 10 g/dL , platelet count &lt; 125,000/mm3 exclude . 8 . Patients use CYP3A4 inhibitor within 3 day randomization end study . R406 metabolize CYP3A4 , ketoconazole increase R406 AUC dose R788 approximately 2 fold . 9 . Patients use CYP3A4 inducer within 3 day randomization end study . Although glucocorticoids inducer , stable dose 10 mg/day allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>R935788</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Syk Kinase</keyword>
</DOC>